Edge Advisors’s Cocrystal Pharma COCP Stock Holding History

Edge Advisors’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$0	Hold	14	–	–	﹤0.01%	838
2018 Q1	$0	Buy	+14	New	+$874	﹤0.01%	875

Other funds holding COCP

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return

KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Edge Advisors's COCP Position: Q2 2018 in Review

Edge Advisors held its Cocrystal Pharma (COCP) position steady in Q2 2018 at 14 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #838.

Edge Advisors first reported a position in COCP in Q1 2018 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold COCP as of Q2 2018.

Edge Advisors held 14 shares of Cocrystal Pharma worth $0 as of Q2 2018.
Edge Advisors left its Cocrystal Pharma share count unchanged in Q2 2018.
Cocrystal Pharma made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #838 holding.
Edge Advisors first reported a position in Cocrystal Pharma in Q1 2018 and has held it in 2 quarters since.
22 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.